M&A/Joint Venture

  • Mylan in its combination with Upjohn, Pfizer’s off-patent branded and generic established medicine business, creating a new global pharmaceutical company.
  • Eddingpharm on its acquisition of two antibiotic products sold by Eli Lilly in China, Ceclor and Vanocin, as well as its Ceclor manufacturing facility in Suzhou with a total transaction value of US$375 million.
  • WuXi AppTec in its establishment of a joint venture with Mayo Clinic, a non-profit worldwide leader in medical care, research and education.
  • China Everbright on its acquisition of 22.4% of the shares in LifeTech, a leading cardiovascular device manufacture in China listed on the Hong Kong Stock Exchange for US$126 million.
  • Bluesail Medical Co. on its acquisition of 93.37% of the shares in Biosensors International, a medical device company established in Bermuda, for RMB5.9 billion.
  • Bayer on its acquisition of Dihon Pharmaceutical Group for about RMB3.6 billion. This deal was recognized as Deal of the Year 2015 by China Business Law Journal.
  • Bayer HealthCare China in its integration with the onshore part of Merck OTC Business, following Bayer’s global acquisition of Merck OTC department.
  • Yunfeng Capital and Alibaba Group in the privatization of iKang Healthcare Group, Inc., a leading health inspection chain in China, from NASDAQ.
  • Centurium Capital and other investors in the proposed privatization of China Biologic Products Holdings Inc., a leading fully integrated plasma-based biopharmaceutical company in China, from NASDAQ.